1. Home
  2. EWTX vs AMRC Comparison

EWTX vs AMRC Comparison

Compare EWTX & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • AMRC
  • Stock Information
  • Founded
  • EWTX 2017
  • AMRC 2000
  • Country
  • EWTX United States
  • AMRC United States
  • Employees
  • EWTX N/A
  • AMRC N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • AMRC Engineering & Construction
  • Sector
  • EWTX Health Care
  • AMRC Consumer Discretionary
  • Exchange
  • EWTX Nasdaq
  • AMRC Nasdaq
  • Market Cap
  • EWTX 1.5B
  • AMRC 1.3B
  • IPO Year
  • EWTX 2021
  • AMRC 2010
  • Fundamental
  • Price
  • EWTX $15.57
  • AMRC $25.96
  • Analyst Decision
  • EWTX Buy
  • AMRC Buy
  • Analyst Count
  • EWTX 9
  • AMRC 7
  • Target Price
  • EWTX $39.89
  • AMRC $21.71
  • AVG Volume (30 Days)
  • EWTX 782.1K
  • AMRC 561.3K
  • Earning Date
  • EWTX 08-07-2025
  • AMRC 08-04-2025
  • Dividend Yield
  • EWTX N/A
  • AMRC N/A
  • EPS Growth
  • EWTX N/A
  • AMRC 9.21
  • EPS
  • EWTX N/A
  • AMRC 1.17
  • Revenue
  • EWTX N/A
  • AMRC $1,858,653,000.00
  • Revenue This Year
  • EWTX N/A
  • AMRC $9.95
  • Revenue Next Year
  • EWTX N/A
  • AMRC $9.35
  • P/E Ratio
  • EWTX N/A
  • AMRC $22.14
  • Revenue Growth
  • EWTX N/A
  • AMRC 22.85
  • 52 Week Low
  • EWTX $10.60
  • AMRC $8.49
  • 52 Week High
  • EWTX $38.12
  • AMRC $39.68
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 64.68
  • AMRC 70.54
  • Support Level
  • EWTX $13.93
  • AMRC $24.88
  • Resistance Level
  • EWTX $15.12
  • AMRC $26.73
  • Average True Range (ATR)
  • EWTX 0.71
  • AMRC 1.09
  • MACD
  • EWTX 0.10
  • AMRC 0.10
  • Stochastic Oscillator
  • EWTX 90.29
  • AMRC 84.09

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About AMRC Ameresco Inc.

Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.

Share on Social Networks: